Texas Equine Veterinary Association

Remuda Summer 2017

Texas Equine Veterinary Association Publications

Issue link: http://aspenedgemarketing.uberflip.com/i/1092529

Contents of this Issue

Navigation

Page 21 of 23

www.texasequineva.com • Page 22 There is NO GENERIC ADEQUAN ® INDICATIONS For the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. IMPORTANT SAFETY INFORMATION There are no known contraindications to the use of intramuscular Adequan ® i.m. brand Polysulfated Glycosaminoglycan in horses. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Please see Full Prescribing Information at www.adequan.com. Adequan ® and the Horse Head design are registered trademarks of Luitpold Pharmaceuticals, Inc. © Luitpold Animal Health, division of Luitpold Pharmaceuticals, Inc. 2016. AHD227 Iss. 4/2016 The ONLY FDA approved equine PSGAG for the intramuscular treatment of non-infectious degenerative joint disease (DJD) of the carpal and hock joints proven to: • DIMINISH the destructive processes of degenerative joint disease • REVERSE the processes which result in the loss of cartilage components • IMPROVE overall joint function and associated lameness Available for order! For more information about equine joint health and treatment with Adequan ® i.m., please visit www.adequan.com.

Articles in this issue

Links on this page

view archives of Texas Equine Veterinary Association - Remuda Summer 2017